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Mammalian adult stem cells show, in vitro, extensive differentiative ability and may represent a versatile tool for
tissue regenerative purposes, even after long-term storage. Multipotent stem cells isolated from horse blood have
been shown to possess the capacity to differentiate into diverse mesenchymal lineages although their full char-
acterization is still at an early stage. The aim of this study was to examine the effects of cryopreservation on
stemness characteristics of adult equine mesenchymal stem cells isolated from peripheral blood (ePB-MSC). Each
sample of ePB-MSC was analyzed immediately and then after being frozen in liquid nitrogen for 10–12 months.
After cryopreservation, cells conserved their morphology, alkaline phosphatase positivity, telomerase activity,
karyotype profile, proliferation rate, and CD expression pattern. We characterized ePB-MSC as cells expressing
CD44, CD90, CD117, and CD13, but not CD34 and CD45. Finally, freezing and storing ePB-MSC did not change
their adipogenic, osteogenic, and myogenic differentiative potential, as analyzed by histochemistry, immuno-
fluorescence, and polymerase chain reaction expression analyses. Overall, our results demonstrate that cryo-
preservation of ePB-MSC provides a convenient tool for in vitro applications, because cryopreserved cells possess
the same stem characteristics as freshly isolated cells. Moreover, the feasibility of maintaining stem cell features of
ePB-MSC after long-term storage has important implications for autologous cellular-based therapy in veterinary
medicine.
Introduction
Adult mesenchymal stem cells (MSC) are character-ized by a fibroblast-like morphology, long-term self-
renewing capacity, and an ability to generate many mature
and specialized cell types.1 MSC have been isolated from
bone marrow,2 peripheral blood,3 umbilical cord,4,5 adipose
tissue,6 and dermis.7 MSC derived from bone marrow, um-
bilical cord blood, and adipose tissue have been defined as
cells expressing stem cell markers CD44, CD29, CD90, and
CD73, but not expressing hematopoietic markers (CD14,
CD34, and CD45) or the stem cell marker CD133.8,9 Further,
these cells possess the peculiar ability to differentiate along
several cell lineages, including chondrocytes,10 adipocytes,
and myoblasts.11,12 Bone-marrow-derived stem cells may also
be attracted to distant peripheral sites after intense injuries
and participate in the tissue repair of damaged areas.1,13 The
clinical potential of MSC has been demonstrated in the treat-
ment of bone defects14 and infarcted heart,15 and in tracheal
regeneration.16 Moreover, other studies showed that stem
cells can regenerate the retina,17 the cornea,18 and muscle.19
Among different sources of adult stem cells of mesenchymal
origin, peripheral blood hematopoietic stem cells (HSCs) are
the major source of stem cells used for transplantation
studies.20
In equine medicine, the tissue of choice as source of stem
cells is still bone marrow, but peripheral blood may provide a
promising tool for achieving clinical advantages because of
its lower invasivity, easier accessibility, and plasticity. Indeed,
the ability to differentiate toward nonhematopoietic tissue
was recently proven for equine multipotent stem cells isolated
from peripheral blood.21 Nevertheless, expression of CD
markers by equine MSC that are isolated from peripheral
blood (ePB-MSC) is still unknown, and only stem cells iso-
lated from horse umbilical cord blood have been thus char-
acterized by flow cytometry.22
The horse is an important animal model because of its in-
herent value in sports, breeding, and leisure activities, and
because it is particularly inclined to develop skeletal muscle
diseases. Therefore, ePB-MSC could be used in cell-based
therapies for the treatment of tendon, ligament, bone pathol-
ogies, and cartilage defects, because it is often not possible to
achieve a restitutio ad integrum.
Another crucial point for applicability of stem cells in
clinical veterinary medicine is the possibility of long-term
storage, as functional cryopreservation could provide an
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available pool of cells for basic research and feasibility test-
ing. Although the cryopreservation of HSCs and umbilical
cord blood cells is a common method that provides advan-
tages for cellular therapies23 in human medicine, in equine
veterinary medicine, only adipose-tissue-derived progenitors
cells have been demonstrated to maintain their properties
after cryopreservation.24 A fundamental objective of this
work was to verify the proliferative capacity of ePB-MSC
and their ability to differentiate into different cell types and
to assess their ability to maintain stem features after long-
term cryopreservation.
In this study, we have examined the effect of cryopreser-
vation on ePB-MSC stemness by means of a complete cellular
characterization, utilizing phenotype morphology, vitality
assay, telomerase activity, and flow cytometry. Further, the
capacity of these multipotent cells to differentiate into adipo-
cytes, osteoblasts, and myoblasts has been compared in both
fresh and cryopreserved cells. The possibility of cryopreser-
ving ePB-MSC for a long time may make use autologous
stem cells for equine therapies feasible, and the establishment
of a veterinary cell bank a priority.
Materials and Methods
Isolation and culture of ePB-MSC
Peripheral blood samples obtained from horses (n¼ 25)
aged 4–20 years were collected in tubes containing anti-
coagulants Li-heparin. To isolate mononuclear cells, peripheral
blood was diluted 1:1 with phosphate-buffered saline (PBS)
and carefully placed on Ficoll-paque solution (Amersham
Biosciences, Piscataway, NJ). After density centrifugation
(R.C.F. Meter4233R; A.L.C International S.r.l., Cologno
Monzese, Italy) at 1600 g for 20 min without brake, cells were
removed from the interphase and washed twice with PBS.
Cells obtained from each 100 mL of blood were plated in
25 cm2 culture flasks (Falcon; BD Biosciences) in noninduc-
tive medium consisting of Dulbecco’s modified Eagle’s me-
dium (DMEM D5671; Sigma-Aldrich S.r.l., Milan, Italy) with
20% fetal bovine serum (FBS; ECS0180-L; Euroclone, Milan,
Italy), penicillin and streptomycin (Sigma-Aldrich S.r.l.), and
glutamine (Sigma-Aldrich S.r.l.), and incubated ( Jouan
IG150; Laborgerateborse, Burladingen, Germany) in an at-
mosphere of humidified air and 5% CO2 at 378C. After
overnight incubation, nonadherent cells were removed and
fresh medium was added to the flasks. After 2–3 weeks, the
developed colony-forming units of adherent cells were re-
covered and replated for amplification, and the medium was
changed every 3 days. Isolated cells close to confluence were
quantified and subcultured in 10% FBS. To evaluate MSC
properties, human dermal fibroblasts were used as negative
controls in differentiation studies.
Cryopreservation and thawing of ePB-MSC
At passages 2–3, ePB-MSC were frozen at a concentration
of 2106 cells=cryovial, which we refer to as cryopreserved
P1 cells. ePB-MSC were resuspended in cryopreservation
medium (90% FBS and 10% dimethyl sulfoxide) (Sigma-
Aldrich S.r.l., Milan, Italy) using Mr. Frosty (Nalgene,
Roskilde, Denmark) decreasing 18C=min until 808C; at
this temperature, cells were held for 1 week and then
transferred to a liquid nitrogen tank for long-term storage.
The thawing procedure was performed after 10 or 12
months: cryovials with ePB-MSC were placed in a 378C
water bath for 1–2 min and then centrifuged at 1600 g for
10 min and washed with noninductive medium to eliminate
dimethyl sulfoxide. The cells were then seeded into 25 cm2
flasks in noninducted medium.
Proliferation assay
To determinate the cellular proliferation rate a cell pro-
liferation kit II (XTT)-based (Roche, Milan, Italy) colorimetric
assay was used. Cells (5103) were grown for 9 days in 96-
well tissue culture plates. Each day, cells in selected wells were
incubated with the yellow XTT solution for 2 h. After incuba-
tion with XTT, the metabolically active cells develop an orange
formazan product, which was quantified using an enzyme-
linked immunosorbent assay plate reader (Spectra Count;
Perkin Elmer, Milan, Italy). The amount of orange formazan
formed was directly correlated to the number of living cells.
The population doubling time
The population doubling level (pdl) was determined in
continual subculture from a known number of cells. At each
subcultivation the pdl was calculated with the equation log
(Nf=Ni)=log2, where Ni and Nf are initial and final cell
numbers, respectively. The population doubling time was
calculated using the equation x¼ t(h)=pdl.
Alkaline phosphatase detection
The ePB-MSC were washed at 50% confluence with PBS
and fixed with 4% paraformaldehyde (PFA) for 10 min at
room temperature. The alkaline phosphatase (AP) enzyme
activity was assayed using a commercial AP detection kit
(Kit SIGMA FAST BCIP=NBT; 5-bromo-4chloro-3-indolyl
phosphate=nitro blue tetrazolium; Sigma-Aldrich S.r.l.).
Karyotyping
Karyotype studies were performed on metaphase cells
derived from ePB-MSC (among passage 1 or P1 and passage
8 or P8). Dividing cells were arrested in metaphase with
0.1 mg=mL colcemid (Sigma-Aldrich S.r.l.) overnight; cells
were subsequently incubated in hypotonic solution for
15 min (0.075 M KCl, pH 7), and fixed with methanol=acetic
acid (3=1, vol=vol). Cells were then stained with Giemsa
solution and analyzed for chromosome number.
Telomerase assay
Telomerase activity was detected by TeloExpress Quanti-
tative Telomerase Detection Kit (Express Biotech International,
Thurmont, MD). Appropriate amount of cells were resus-
pended in TeloExpress lysing buffer according to the manu-
facturer’s instruction. Samples (n¼ 3) were analyzed in
triplicate using an AB 7500 real-time polymerase chain reac-
tion (PCR) instrument (Applied Biosystem, Foster City, CA).
The telomerase positive control was provided in the kit, and
negative controls were ePB-MSC heat-inactivated samples.
Flow cytometry assay
Cultured ePB-MSC (n¼ 5) were analyzed between the first
and eighth passage using a fluorescence-activated cell sort-
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ing (FACS) technique. Cells were harvested, washed with
PBS, and incubated for 10 min at 48C in PBS containing 2%
FBS and 2 mM ethylenediaminetetraacetic acid. The cell sus-
pension was then incubated with primary antibodies directed
against the following cell surface markers: CD90 (BD555596;
BD Biosciences), CD44 (BD550989; BD Biosciences), CD13
(BD555394; BD Biosciences), CD140a (BD556002; BD Bios-
ciences), and CD117 (BD553355; BD Biosciences), each of
which was conjugated with phycoerythrin, and against CD34
(ABD MCA1825F) and CD45 (BD553079; BD Biosciences)
conjugated with fluorescein isothiocyanate (FITC). Cells
were suspended in 300 mL PBS in FACS tubes (Falcon; BD
Bioscience). Mouse isotype IgG1 and IgG2a and rat isotype
IgG2a were employed as controls (BD Biosciences). For each
sample, 200,000 cells were passed through a FACScan Canto
Flow cytometer (BD Biosciences) and analyzed using FlowJo
software (Tree Star; Oregon Corporation, Ashland, OR).
Differentiative potential of ePB-MSC
Osteogenic differentiation. Osteogenesis was induced
using culture medium supplemented with 1 nM dexa-
methasone (Sigma D1756; Sigma-Aldrich S.r.l.), 10 mM
b-glycerolphosphate (1-800-854; MP Biomedicals Europe,
Illkirch, France), and 50mM ascorbate-2-phosphate (Sigma
A4544; Sigma-Aldrich S.r.l.). Cells were induced in this me-
dium for approximately 21 days and osteogenic medium
was replaced every 2–3 days. After fixation in a 4% solution
of PFA for 30 min, the mineralization of cells was assessed by
von Ko`ssa staining.
Adipogenic differentiation. When cells reached about
80–90% confluence, the ePB-MSC may be induced to dif-
ferentiate using culture medium (DMEM-LG D5921;
Sigma-Aldrich S.r.l.) supplemented with 0.5 mM isobutyl-
methylxanthine (Sigma I5879; Sigma-Aldrich S.r.l.), 200mM
indomethacin (Sigma I7378; Sigma-Aldrich S.r.l.), 0.5 mM
dexamethasone (Sigma D1756; Sigma-Aldrich S.r.l.), and
10 mM insulin (Sigma I6634; Sigma-Aldrich S.r.l.). The me-
dium was changed every 3 days until adipocyte-like cells
were obtained after 21 days of differentiation. Oil Red O
staining was performed to evaluate the degree of ePB-MSC
differentiation. Cells were fixed in a 4% solution of PFA for
30 min, washed with 60% isopropanol, and stained with Oil
Red O solution for 10 min followed by repeated washing
with water.
Myogenic differentiation. The ePB-MSC were cultured in
differentiation medium consisting of high glucose DMEM
(DMEM D5671; Sigma-Aldrich S.r.l.) supplemented with 2%
horse serum (CCVCHL00-01; Eurobio, Courtaboeuf, France)
and 50mM hydrocortisone (H888; Sigma-Aldrich S.r.l.) for 15
days. Cells were fixed with 4% PFA, and after an incubation
with 0.1% Triton X-100, a primary antibody against Myf5
(Santa Cruz sc-320; D.B.A., Milan, Italy) or MyoD (Santa Cruz
m-318; D.B.A.) was added at 1:100 dilution and incubated for
1 h at room temperature. After washing three times with PBS,
primary antibodies were detected using species-specific fluo-
rochrome-conjugated antibodies (FITC) diluted 1:400 in PBS
(Alexa A11001; Invitrogen Life Technologies). Immunostain-
ing controls were performed using the same conditions but
omitting primary antibody.
RNA isolation, standard PCR, and DNA sequencing
ePB-MSC were maintained in adipogenic and osteogenic
differentiation medium for 3 weeks or in myogenic differ-
entiation medium for 2 weeks. From each cell population
total RNA was extracted using Trizol reagent (Gibco-BRL,
Gaithersburg, MD). Total RNA was reverse-transcribed us-
ing Superscript protocols (Invitrogen Life Technologies)
and a mixture of random hexamers. The cDNAs were used
as template for ordinary PCR. Different PCRs were con-
ducted using specific primers designed with Primer Express
software and ordered online (www.eurofinsdna.com). Per-
oxisome proliferator-activated receptor-gamma (PPARg2)
153 bp product (forward primer: 50-ATTACGGAGTTCAT
GCCTGTG-30; reverse primer: 50-GTTTTCACAAGTGCCTT
TCGG-30) was analyzed for adipogenic samples; SPP1 (se-
creted phosphoprotein 1, osteopontin) 285 bp product (for-
ward primer: 50-AAGCCTGATCCGTCTCAGAA-30; reverse
primer: 50-ACGTCGGTGGAAAAATCAG-30) was analyzed
for osteogenic samples; desmin 186 bp product (forward
primer: 50-GCTTCAGGAACAGCAAGTCC-30; reverse
primer: 50-CGCAGTGCATCATTGTTCTT-30) was analyzed
for myogenic differentiation. A b-actin fragment of 185 bp
product (forward primer: 50-CCATCTACGAGGGGTACG
CCC-30; reverse primer: 50-TGCTCGAAGTCCAGGGCGA
CGTA-30) was amplified to exclude a genomic contamination
and to validate the purity of cDNA. PCR products were se-
quenced by the BMR Genomics (Bio Molecular Research)
(sequencing service) to confirm the identity of PPARg2,
SPP1, and desmin. As negative controls human fibroblasts
were maintained in adipogenic, osteogenic, and myogenic
differentiation medium for 3 weeks, and expression of
PPARg2, SPP1, and desmin was analyzed, respectively, us-
ing the following specific primers—forward: 50-TTCTTCAT
GGAAGTGTTGGCTAT-30, reverse: 50-TTTCTCGATCTTTG
GGCATG-30; forward: 50-CATATGATGGCCGAGGTGAT
AG-30, reverse: 50-GAATGGTGCATACAAGGCC-30; for-
ward: 5-TTGACCTGGAGCGCAGAATT-30, reverse: 50-TAA
GCCAGACCTCACTGCCG-30.
Statistical analysis
Data are expressed as the mean standard deviation.
Normality of the data was confirmed using the Kolmogorov–
Smirnov test (¼ 5%). Statistical analysis was performed
using the paired Student t-test (SPSS software, version 11.0;
SPSS, Chicago, IL). The level of statistical significance was set
at p 0.05 for all analyses.
Results
Isolation, expansion, and morphology of ePB-MSC
ePB-MSC were successfully isolated from peripheral
blood samples of 11 horses (from total sampling of 25 horses).
Fifteen to 20 days after isolation and with only 3 medium
changes, some clones were growing. However, the effi-
ciency of colony formation was quite low, with about 1.7 0.6
(colony-forming unit) per 106 nucleated cells. Cells were re-
cultured in growth medium for further expansion, with reg-
ular passages when cultures reached a 70–80% confluence.
The ePB-MSC achieved confluence in 3–4 days for cells of
passages 1 to 4, and in 5–6 days for later passages. Each
sample that was successfully isolated was cryopreserved.
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After thawing, cell passages were compared with fresh
cells isolated from the same horse. These cells maintained a
fibroblast-like phenotype when expanded in culture (Fig. 1A).
The cryopreserved ePB-MSC, after being thawed, seeded, and
cultured for 2 days, presented the same fibroblast-like mor-
phology as fresh cells (Fig. 1B). Both fresh and cryopreserved
cells showed strong AP staining, an embryonic marker for
stemness (Fig. 1C, D). The cell viability of ePB-MSC was de-
termined by XTT proliferation assay. Fresh and cryopre-
served cells (before P8) were analyzed for their proliferation
potential. The growth curve for fresh cell populations (n¼ 7)
was characterized by an initial lag phase (48 h) followed by a
log phase, whereas cryopreserved cell populations (n¼ 7)
immediately grew logarithmically (Fig. 2A). To determine the
proliferation potential, the population doubling time of fresh
and cryopreserved cells was calculated at passages P1, P4,
and P8 (Fig. 2B). Our results showed that the doubling time of
cells increased with passage number and that cryopreserved
cells doubled significantly more rapidly than fresh cells at P1
(fresh: P1, 30.57 1.3; P4, 40.37 2.5; P8, 47.35 4.3; cryo-
preserved: P1, 18.39 2.4; P4, 30.21 3.6; P8, 46.77 4.4).
To investigate and compare the self-renewal ability of
fresh and cryopreserved ePB-MSC, we evaluated telomerase
activity and its stability at passages 1 and 8. Three samples of
fresh and cryopreserved cells presented a telomerase activity
similar to the positive control supplied by TeloExpress
Quantitative Telomerase Detection Kit and this activity did
not change between passage 1 and 8. Although telomerase
activity was numerically higher in fresh cells than in cryo-
preserved, this difference was not significant (Fig. 3). We also
observed a normal karyotype in both fresh ePB-MSC and
cryopreserved cells at passage 8, for which time 64 chro-
mosomes were counted (Supplemental Fig. 1 available online
at www.liebertonline.com/ten).
Immunophenotype
Expression of cell surface antigens was characterized in
fresh and cryopreserved ePB-MSC between P3 and P8 (n¼ 5)
by flow cytometry analysis. Cell populations, defined on the
basis of forward and side scatter, showed similar cell com-
plexity in fresh and cryopreserved ePB-MSC (Supplemental
Fig. 2; supplemental figures available online at www
.liebertonline.com/ten). Shown in Figure 4 are representative
histograms of fresh and cryopreserved ePB-MSC immuno-
phenotypes, together with a percentage analysis of cell anti-
gens, confirming the conserved immunophenotype of frozen
cells. Fresh and cryopreserved cells were highly positive for
extracellular matrix protein CD90 (100% 0 for fresh,
100% 0 for cryopreserved), and the hyaluronate receptor
CD44 (97.9% 2.9 for fresh, 98.3% 2.9 for cryopreserved).
The ePB-MSC expressed membrane glycoprotein CD13 anti-
gen, although its expression decreased slightly after cryo-
preservation (78% 11 for fresh, 61% 9.9 for cryopreserved).
Cells expressed the CD117 antigen (c-Kit receptor) (63.8%
35.7 and 73.5% 36 for fresh and cryopreserved cells, re-
spectively). This cytokine receptor is expressed on the surface
of HSCs, although with high variability. Expression of all
analyzed antigen markers did not change significantly be-
tween fresh and cryopreserved cells. In addition, the analysis
FIG. 1. Morphology of adherent PB-MSC. (A) Fresh stem cells isolated from peripheral blood showed a fibroblast-like
phenotype. (B) After 12 months of cryopreservation, cells presented the same morphology as shown in (A). (C) Fresh ePB-
MSC showed a strong positivity for alkaline phosphatase. (D) Cryopreserved cells presented an equal staining intensity. Scale
bars: (A, B) 300 mm; (C, D) 500mm. ePB-MSC, equine peripheral blood mesenchymal stem cells. Color images available online
at www.liebertonline.com=ten.
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showed no staining for hematopoietic lineage markers CD34
and CD45.
Differentiative potential
The multilineage differentiation capability of ePB-MSC
was evaluated before and after cryopreservation using line-
age-specific induction factors to examine differentiation
toward the adipogenic, osteogenic, and myogenic lineages.
Differentiative pathways were qualitatively assessed using
gene expression and imunohistochemistry analyses.
We examined expression of mRNA for specific marker
genes in fresh and cryopreserved ePB-MSC after induction of
differentiation with adipogenic-, osteogenic-, and myogenic-
specific media (Fig. 5). Human fibroblasts were used as a
negative control, and b-actin mRNA was used as an internal
PCR control (Supplemental Figs. 3 and 4; supplemental
figures available online at www.liebertonline.com/ten). The
cells induced into an adipogenic fate expressed PPARg2, a
nuclear receptor isoform present exclusively in adipose tis-
sue. Expression of osteopontin (SPP1), an extracellular
structural protein and an organic component of bone, was
analyzed to evaluate osteogenic induction. Expression of
desmin, a protein of intermediate filaments present in skel-
etal muscle tissue, was investigated to evaluate the myogenic
differentiation of ePB-MSC. Among investigated genes, PCR
results did not show differences between fresh and cryo-
preserved ePB-MSC (Fig. 5). Further, the same tissue-specific
gene markers were not expressed in noninduced cells or in
fibroblasts that were treated with induction (differentiation)
medium (Supplemental Figs. 3 and 4). To confirm the iden-
tity of the gene markers employed, all PCR bands were
subcloned, sequenced, and BLASTed against GenBank data-
base; all sequences showed a total identity with the targeted
equine genes (data not shown).
The ePB-MSC cultivated in adipogenic differentiation
medium showed the presence of lipid vacuoles as evidenced
by Oil Red O staining (Fig. 6A, B). Osteogenic differentiation
resulted in an increase of calcium deposits, as assessed by
von Kossa staining (Fig. 6C, D). Myogenic commitment was
indicated by nuclear Myf5 positivity together with myoblast
alignment (Fig. 6E, F). Another early marker of myogenic
differentiation (MyoD, data not shown) was tested and
provided supportive evidence for myogenic differentiation
by staining nuclei of myoblast-induced cells.
Discussion
Adult stem cells have been isolated from several tissues25
and their huge potential is still being tested in both human
and veterinary medicine.26 HSCs are used in human medi-
cine for autologous and allogenic transplantation to restore
bone marrow cell populations because they provide a faster
and more efficient outcome than that obtained by trans-
plantation of marrow-derived stem cells.27 Circulating stem
cells may also traffic to sites of tissue injuries, which may
lead to infiltration of the damaged tissue and regeneration of
nonhematopoietic cell types.28 In the horse, Giovannini et al.21
and Koerner et al.29 proved, in vitro, the capacity of putative
stem cells isolated from peripheral blood to differentiate into
nonhematopoietic lineages; the latter authors referred to
these cells as fibroblast-like21 or progenitor29 cells, and no-
menclature is still inconsistent. In the current study, we have
used the acronym ePB-MSC (equine peripheral blood mes-
enchymal stem cells) because the term ‘‘mesenchymal’’ has
gained wider consensus in the scientific community.30 The
plasticity of these cells raises the possibility of using them as
an alternative source of stem cells to treat many pathologies
of competitive horses that are difficult to resolve, such as
osteochondrosis, subchondral cystis, and tenodesmic in-
juries.
In this work we presented comparative data for fresh and
cryopreserved ePB-MSC, a well known class of adult stem
cells of mesenchymal origin. Our study provided a full char-
acterization of these cells, including a CD expression assay,
not previously performed in horse peripheral blood. We
confirmed that ePB-MSC are able to differentiate into adi-
pocytes, osteoblasts, and myoblasts. To our knowledge, this
is the first demonstration of myoblast differentiation from
ePB-MSC. We have also demonstrated that cryopreserved
cells show similar stem characteristics as fresh cells.
We have analyzed morphological characteristics and
proliferative ability of different clones from fresh and cryo-
preserved ePB-MSC. Generally, these cells presented a fi-
broblastoid appearance and possessed proliferative behavior
FIG. 2. Growth kinetics and population doubling time of
ePB-MSC. (A) Fresh cells isolated from horse blood samples
and cryopreserved cells (n¼ 7) thawed after 12 months were
seeded in triplicates into 96-well dishes and analyzed with a
colorimetric assay cell proliferation kit II (XTT). The graph
shows the cell number average respect to culture time. (B)
Values shown are the averagedeviation standard of the
population doubling time of fresh and cryopreserved cells
(n¼ 7) at passages P1, P4, and P8. The paired Student’s t-test
t was used for each passage to compare fresh versus cryo-
preserved cells (*p< 0.05).
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that is similar to other mammalian MSC.31 Thawed cells did
not show a lag phase of proliferation that is typical of freshly
cultured MSC, apparently because these cryopreserved cells
were already growing logarithmically when frozen. Indeed,
to obtain optimal cryopreservation it is necessary to utilize a
very high number of cells obtained from passages 2–3 (which
correspond to log phase). Nevertheless, based on growth
kinetics and population doubling time, our data suggest that
ePB-MSC maybe easily expanded while maintaining their
viability even after cryopreservation. We found that ePB-
MSC presented a similar AP activity in both fresh and
cryopreserved cells. Because AP is a characteristic enzyme
FIG. 3. Telomerase activity of ePB-MSC. (A) Three fresh cell populations (E, F, and G) were analyzed at passages P1 and P8.
(B) Three cryopreserved cell populations (B, C, and D) were analyzed at passages P1 and P8. A1, negative control; A2,
positive control. In graphs (A) and (B), x-axis corresponds to number of cycles and y-axis corresponds to normalized reporter
(Rn¼ the ratio of fluorescence emission intensity of the reporter dye to the fluorescence intensity of the passive reference dye).
The histograms show the Ct average standard deviation of the three populations at passages 1 and 8. The paired Student’s
t-test t was used for each passage to compare fresh versus cryopreserved cells. Color images available online at www
.liebertonline.com=ten.
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for bone tissue, the observed enzymatic activity may indicate
an inherent natural tendency toward osteogenic differentia-
tion.32 Moreover, AP is considered an embryonic marker
because increased activity in embryonic stem cells corre-
sponds to higher capacity for colony formation.33 Normal
karyotypic profiles indicated that freshly isolated and cryo-
preserved ePB-MSC did not possess chromosome abnor-
malities and measures of telomerase activity were indicative
of the stem cell character of the cell populations evaluated.
Stem cells require de novo synthesis of telomere repeats
FIG. 4. Detection of CD markers on cell membrane. Both
fresh and cryopreserved cells were tested for several anti-
bodies. Cells were positive for CD90, CD44, CD13, and
CD117, whereas no expression was detected for CD34 and
CD45. (A) Representative diagrams showing fluorescence-
activated cell sorting evaluation in fresh and cryopreserved
cells. The isotype control is shown as a black-line histogram.
(B) The histograms show the average, expressed in percent-
age, of CD presence in fresh and cryopreserved ePB-MSC.
The paired Student’s t-test was used for each antigen to
compare fresh versus cryopreserved cells.
‰
FIG. 5. Expression profile of differentiative gene markers in
fresh and cryopreserved cells induced toward the adipogenic
(lanes 1 and 2), osteogenic (lanes 3 and 4), and myogenic
(lanes 5 and 6) fate. (A) Fresh cells were tested with spe-
cific primers for peroxisome proliferator-activated receptor-
gamma2 (lane 2), secreted phosphoprotein 1 (lane 4), and
desmin (lane 6). (B) Cryopreserved cells were tested with the
same specific primers for peroxisome proliferator-activated
receptor-gamma2 (lane 2), secreted phosphoprotein 1 (lane 4),
and desmin (lane 6). b-Actin was used as internal control
(lanes 1, 3, and 5). The molecular size standard used was the
1Kb Plus DNA Ladder (Invitrogen, Gaithersburg, MD). Scale
bars indicate 200 bp.
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to maintain their ability to divide; this is achieved by the
transcriptase activity of telomerase, which is low in normal
somatic cells but increased in a variety of malignancies and
in immortalized=stem cells.34 The capacity of telomerase
to elongate telomeres (telomerase enzymatic activity) was
found in cell lysates of fresh and cryopreserved cells, and
it was unchanged between passage 1 and 8. Although
fresh cells presented numerically greater telomerase activity
than cryopreserved cells, the means were not signifi-
cantly different, and both fresh and cryopreserved cells
maintained an elevated growth potential. The normal, heal-
thy status of frozen cells was also confirmed by their normal
karyotype.
Another key finding of the present research pertains to the
characterization of ePB-MSC using flow cytometry (FACS).
The surface markers for human and mouse HSCs have been
identified, whereas in the horse, the CD assay has been
performed only in mesenchymal stem cells derived from
umbilical cord blood.22 We employed commonly used mes-
enchymal markers to define the horse stem cell population
found in peripheral blood.12 Our study showed, for the first
time in horse peripheral blood, that ePB-MSC express CD44,
CD90, and CD13, whereas the progenitor hematopoietic
markers CD34 and CD45 were not detected. CD117 was ex-
pressed in horse ePB-MSC although its expression in mesen-
chymal stem cells (MSC) from other mammals has been
controversial. Some authors showed that MSC do not express
CD117,35 whereas others determined that embryonic stem
cells, HSCs, and MSC are positive for this marker.36 Im-
portantly, we did not find significant differences between
FIG. 6. Differentiative potential of horse ePB-MSC. Adipogenic induction in fresh (A) and cryopreserved (B) cells is evident
in ePB-MSC with Oil Red O staining; in both images small lipid droplets are visible inside the cells (arrows). Osteogenic
induction in ePB-MSC was verified with von Kossa staining: both fresh (C) and cryopreserved (D) cells showed a strong
positive reaction since the calcium deposits (asterisks) increased in the culture. Myogenic induction in fresh (E) and cryo-
preserved (F) ePB-MSC. The myogenic commitment was evident in ePB-MSC since the nuclear positivity for Myf5 (arrow-
heads) and myoblasts alignment (arrows). Scale bars: (A, B) 40mm; (C, D) 100 mm; (E, F) 75 mm. Color images available online
at www.liebertonline.com=ten.
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fresh and cryopreserved ePB-MSC concerning cell size (Sup-
plemental Fig. 2; supplemental figures available online at
www.liebertonline.com=ten) or CD expression pattern.
As suggested by several studies,10,12,37 MSC possess the
potential to differentiate into multiple mesodermal lineages
after exposure to specific culture conditions. We verified that
horse multipotent stem cells are able to differentiate into
three different lineages. Adipogenic induction of the ePB-
MSC in culture for 21 days resulted in formation of small
lipid vacuoles, suggesting that differentiation was in its
initial stages. Expression of PPARg2, a fat-specific transcrip-
tional factor that functions in preadipocyte commitment,
confirmed the adipogenic differentiation. Incubation of ePB-
MSC with osteogenic induction medium caused the forma-
tion of cell aggregates and matrix mineralization that was
indicated by the calcium specific staining (using von Kossa
stain) and by expression of SPP1 mRNA (osteopontin).
Finally, hydrocortisone addition provoked the differentiation
of ePB-MSC toward the myogenic pathway. After 15 days
of induction, ePB-MSC formed multinucleated fibers that
morphologically resembled myotubes and that expressed the
structural protein desmin. The myogenic commitment was
further manifested by expression of two nuclear myogenic
transcription factors: Myf5, which promotes the myogenic
specification of undifferentiated cells, and MyoD, which
initiates the differentiative myogenic program.38 Addi-
tionally, this is the first report to investigate the stemness
features of cryopreserved ePB-MSC. We observed the fol-
lowing similar characteristics, at least up to passage 8, be-
tween fresh and ePB-MSC cryopreserved cells: (i) growth
and morphology was not affected; (ii) the immunophenotype
expression pattern was the same; (iii) the plasticity of ePB-
MSC was not reduced.
Recent progress in the isolation and characterization of
adult stem cells led to the development and testing of ther-
apeutic strategies in a variety of human clinical applications.
Stem cell therapy involves the transplantation of autologous
or allogenic stem cells. Some examples of the therapeutic use
of different tissue-derived MSC included cartilage repair,39
orthopedic40 and coronary artery diseases,41 cornea injure
repair,18 and muscular dystrophy.42 In veterinary medicine,
proof of the efficacy of stem cell therapy is still lacking, al-
though efforts have been conducted in horses affected by
orthopedic and tendon injuries.43 A common cryopreserva-
tion method was used in this study that resulted in a low cell
mortality and maintenance of stem cell properties after
thawing. Nevertheless, implementation of different strategies
to improve the cryotolerance of equine MSC is worthy of
investigation. For instance, it is known that cells grown in
monolayer are generally more susceptible to cryoinjuries
than cells grown in suspension.44 The possibility of using
ePB-MSC instead of bone marrow cells for cell-based thera-
pies prompted us to better define the characteristics of un-
differentiated cells present in peripheral blood even after
long-term storage in liquid nitrogen. Considering that the
percentage of circulating stem cells in mammalian peripheral
blood is very low and their successful isolation in equine is
between 33% (Koerner et al.29) and 44% (this study), cryo-
preservation might be regarded as a key tool for enabling
access to MSC from domestic animals. The long-term sta-
bility of cryopreserved stem cells is not very well known,
although in vitro functions of HSCs derived from human
umbilical cord blood was not lost after 5 years of cryopres-
ervation. Moreover, human bone marrow MSC frozen for
2 to 8 years did not show any alterations of their in vivo
engraftment capability.45
In summary, our data suggest that ePB-MSC provide an
accessible and effective source of adult stem cells. These cells
hold the promise of value for regenerative veterinary medi-
cine as well as for laboratory in vitro study, because they
maintain their differentiative potential after cryopreservation.
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